Novartis Pipeline

Benefiting from our continued focus on innovation, Novartis has one of the industry’s most competitive pipelines. Many of these projects, which include new molecular entities as well as additional indications and different formulations for marketed products, are for medicines that could significantly advance treatment standards for patients worldwide. This table provides an overview of selected projects in development. Please note: the Novartis Pipeline data is updated quarterly.

Download the Novartis Pipeline from the 2023 Annual Report (PDF 0.1 MB)

Show Filters
ImmunologyX
Clear All
Showing 28 results
  • AIN457
    Cosentyx®
    Rotator cuff tendinopathy
    Immunology Phase 3 IL17A inhibitor (Anti-interleukin-17 monoclonal antibody)
  • AIN457
    Cosentyx®
    Giant cell arteritis (GCA)
    Immunology Phase 3 2025 IL17A inhibitor (Anti-interleukin-17 monoclonal antibody)
    Supplementary Indication
  • AIN457
    Cosentyx®
    Polymyalgia rheumatica
    Immunology Phase 3 2026 IL17A inhibitor (Anti-interleukin-17 monoclonal antibody)
  • CFZ533
    iscalimab
    Sjögren’s Syndrome (SjS)
    Immunology Phase 2 ≥ 2027 CD40 inhibitor (Blocking, non-depleting, anti-CD40 monoclonal antibody)
    Lead Indication
  • DFV890
    DFV890
    Osteoarthritis
    Immunology Phase 2 NLRP3 inhibitor
    Lead Indication
  • DFV890
    DFV890
    Familial cold auto-inflammatory syndrome
    Immunology Phase 2 NLRP3 inhibitor
    New Indication
  • IGE025
    Xolair®
    Food Allergy
    Immunology Registration IgE Inhibitor (High-affinity anti-IgE monoclonal antibody)
    Supplementary Indication
  • LNA043
    LNA043
    Osteoarthritis (combos)
    Immunology Phase 2 ANGPTL3 Agonist
  • LNA043
    LNA043
    Knee osteoarthritis
    Immunology Phase 2 ≥ 2027 ANGPTL3 Agonist
    Lead Indication
  • LOU064
    remibrutinib
    Chronic spontaneous urticaria, pediatrics
    Immunology Phase 3 BTK inhibitor
  • LOU064
    remibrutinib
    CINDU
    Immunology Phase 3 ≥ 2027 BTK inhibitor
  • LOU064
    remibrutinib
    Chronic spontaneous urticaria (CSU)
    Immunology Phase 3 2024 BTK inhibitor
    Lead Indication
  • LOU064
    remibrutinib
    Hidradenitis suppurativa
    Immunology Phase 2 BTK inhibitor
  • LOU064
    remibrutinib
    Food allergy
    Immunology Phase 2 BTK inhibitor
  • LRX712
    LRX712
    Osteoarthritis
    Immunology Phase 2
    Lead Indication
  • MAS825
    MAS825
    NLRC4-GOF indications
    Immunology Phase 2
    Lead Indication
  • MHV370
    MHV370
    Systemic lupus erythematosus (SLE)
    Immunology Phase 1
    New Indication
  • MHV370
    MHV370
    Sjorgen’s Syndrome (SjS)
    Immunology Phase 2
    Lead Indication
  • MHV370
    MHV370
    Mixed connective tissue disease
    Immunology Phase 2
  • NGI226
    NGI226
    Tendinopathy
    Immunology Phase 2 ≥ 2027
    Lead Indication
Legend

Combination abbreviations:
fulv    fulvestrant
tmx    tamoxifen
gsn    goserelin
NSAI  Non-steroidal aromatase inhibitor
Taf     Tafinlar® (dabrafenib)
Mek   Mekinist® (trametinib)

a    EU filing, approved in US.
b    US filing, approved in EU.
c    US filing, submitted in EU.
d    US pending submission, approved in EU
e    EU filing, submitted in US.

Disclaimer

This information was factually accurate on the date it was published. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information on this page as current or accurate after its publication date. For the latest information on the Novartis' pipeline, readers should visit the News and Investors sections of our website. This information constitutes forward-looking statements relating to Novartis AG's business, including express or implied discussions regarding potential new products, potential new indications for existing products, or regarding potential future revenues from any such products. Such forward-looking statements reflect the current views of Novartis AG regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any new products will be approved for sale in any market, or that any new indications will be approved for existing products in any market, or that such products will achieve any particular revenue levels.

In particular, management's expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays or government regulation generally; the Novartis Group's ability to obtain or maintain patent or other proprietary intellectual property protection, including the uncertainties involved in the US litigation process; competition in general; government, industry, and general public pricing and other political pressures; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.